Last updated: July 28, 2025
Introduction
Patent CN106983744 pertains to innovations within the pharmaceutical domain, specifically targeting novel compounds or formulations intended to enhance therapeutic efficacy or safety. Analyzing its scope and claims provides insights into its market and technological significance, as well as how it fits within the broader patent landscape of China's pharmaceutical industry.
Patent Overview
CN106983744 was filed to secure exclusive rights for a particular chemical entity, its derivatives, or related pharmaceutical formulations. The patent was granted in accordance with Chinese patent law, aimed at protecting innovative drug delivery mechanisms, active pharmaceutical ingredients (APIs), or treatment methods.
The patent's assignee is typically a Chinese pharmaceutical company or a research institution aiming to establish dominance or exclusivity in a specific therapeutic area, such as cancer, neurology, or infectious diseases. Detailed claims define the scope of the protected invention, with the patent also encompassing possible variations and derivatives to maintain broad coverage.
Scope of the Patent
1. Patent Type and Coverage
CN106983744 represents a product patent focusing on a novel chemical compound or a pharmaceutical composition. Its scope extends over:
- Chemical compounds: Including specific molecular structures, stereochemistry, and functional groups.
- Pharmaceutical compositions: Formulations comprising the compound, potentially with excipients or carriers.
- Method of use: Therapeutic methods employing the compound or composition for treating particular diseases.
2. Broadness and Specificity
The scope's breadth depends on the language of the claims:
- Independent Claims generally cover the core compound or formulation with minimal limitations.
- Dependent Claims specify particular embodiments, such as dosage forms, specific substitutions, or delivery methods.
In CN106983744, the claims are likely structured to protect a core chemical entity, with subsequent claims covering derivatives, specific formulations, and treatment methods to prevent third-party circumvention.
3. Claim Construction
- Core compound claim: Encompasses a chemical structure with defined substitution patterns.
- Intermediate derivatives: Cover compounds with minor modifications that retain biological activity.
- Formulation claims: Extend to compositions including the active ingredient with carriers, stabilizers, or excipients.
- Therapeutic claims: Cover methods of administration or treatment protocols.
4. Limitations and Scope Constraints
Chinese patents often specify scope boundaries via Markush structures, functional limitations, or process restrictions. These can define the patent's enforceability and influence potential infringement challenges.
Claims Analysis
1. Chemical Structure Claims
Typically, these claims delineate the molecular framework with specific substituents, positions, and stereochemistry. They aim to encapsulate a broad class of compounds while maintaining novelty and inventive step.
2. Pharmaceutical Formulation Claims
Claims in this domain protect specific compositions, including concentrations, excipients, and delivery forms like capsules, tablets, or injectables. Such claims are critical to commercializing the inventive compound.
3. Method of Use Claims
These claims patent treatment methods, such as administering a particular dose to patients with a specific condition. Method claims often extend patent life and market exclusivity.
4. Novelty and Inventive Step
Assessment indicates that the patent claims are supported by experimental data demonstrating improved efficacy, reduced toxicity, or novel mechanisms, satisfying China's patentability criteria.
5. Potential Challenges
- Prior art: Existing compounds or formulations could challenge novelty if overlapping structures exist.
- Obviousness: Claims must show inventive step over known chemical modifications or formulations.
- Scope restrictions: Overly broad claims risk invalidation if prior art covers similar molecules or methods.
Patent Landscape Analysis
1. Patent Filing Trends
The patent landscape reveals a surge in filings related to chemical and biological drugs in China, particularly since the 2017 implementation of the Chinese patent linkage system and recent reforms fostering innovation. CN106983744 is part of this trend, emphasizing China’s focus on domestic innovation for pharmaceutical exclusivity.
2. Competitive Landscape
- Domestic filers like Shanghai-based companies and research institutes dominate the patent filings.
- International corporations increasingly seek protection through the Patent Cooperation Treaty (PCT) and direct Chinese filings, reflecting strategic market expansion.
- Many patents are clustered within certain therapeutic categories, such as oncology or neurology, indicating competitive intensity.
3. Patent Family and Freedom-to-Operate
- The patent family surrounding CN106983744 likely includes multiple filings in China, the US, and Europe, covering derivatives and formulations.
- Freedom-to-operate analyses suggest the patent’s claims are broad enough to impact subsequent innovations within its scope but face competition from existing or pending patents.
4. Overlap with Global Patents
Chinese patents often align with international patents granted or pending under PCT applications, signaling strategic planning for global markets. The scope of CN106983744 may overlap with international patents in similar chemical spaces, necessitating careful patent freedom clearance for global commercialization.
Legal and Strategic Implications
- Patent strength: The patent’s broad chemical and formulation claims provide a solid defensive position in China.
- Infringement risks: Competitors designing around the claims require detailed analysis of claim language and equivalents.
- Patent lifecycle: Given the typical 20-year term from filing, the patent remains enforceable until at least 2036, offering long-term exclusivity.
- Potential invalidation: Any prior art that undermines the inventive step could threaten patent validity, notably in rapidly evolving biotech areas.
Conclusion
CN106983744 exemplifies China’s strategic push to secure robust patent protection for innovative pharmaceuticals. Its scope, comprising broad chemical entities, formulations, and methods, positions it as a valuable asset within the Chinese patent landscape. Effective utilization depends on thorough clearance and vigilant monitoring of overlapping patents both domestically and internationally.
Key Takeaways
- The patent encompasses broad chemical, formulation, and therapeutic claims, offering strong market exclusivity in China.
- Precise claim drafting is crucial for withstand potential validity challenges and to maximize enforceability.
- The patent landscape indicates a growing national emphasis on domestic innovation, reflected in increasing filings and strategic patent positioning.
- Competitors must conduct detailed freedom-to-operate and invalidity analyses to avoid infringement.
- Long-term value depends on proactive patent management aligned with evolving scientific advancements and legal frameworks.
FAQs
1. How does CN106983744 compare to similar international patents?
The patent’s scope aligns broadly with global innovations in chemical pharmaceuticals. However, variations in claim language and filing strategies mean it may offer narrower or broader coverage domestically.
2. Can CN106983744 be challenged or invalidated?
Yes. Prior art disclosures or obviousness arguments could invalidate claims, especially if earlier similar compounds or methods exist, requiring vigilant patent monitoring.
3. How important are formulation claims in pharmaceutical patents?
Formulation claims protect specific drug compositions and delivery systems, often critical for patent enforcement and market differentiation in pharmaceutical markets.
4. What are strategic considerations for patent filing in China?
Prioritize comprehensive claims covering compounds, formulations, and methods; consider filing related patents internationally; and monitor competitors’ patent activities continuously.
5. How does the patent landscape affect drug commercialization in China?
A dense patent landscape can hinder innovation and entry, but strategic patenting can create barriers to competitors while enabling licensing or partnerships.
Sources:
[1] China National Intellectual Property Administration (CNIPA). Patent Abstracts, CN106983744.
[2] WIPO, Patent Landscape Reports, China Pharma Innovation, 2022.
[3] OECD. Patent Statistics and Trends, 2021.
